deltatrials
Completed PHASE1 NCT00004232

Bone Marrow and Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer

Augmenting Bone Marrow With CD34 Enriched Peripheral Blood Hematopoietic Stem Cells for Allogeneic Transplantation of Hematologic Malignancies

Sponsor: National Cancer Institute (NCI)

Conditions Chronic Myeloproliferative Disorders Graft Versus Host Disease Leukemia Lymphoma Multiple Myeloma and Plasma Cell Neoplasm Myelodysplastic Syndromes Precancerous/Nonmalignant Condition
Interventions allogeneic bone marrow transplantation cyclosporine filgrastim methylprednisolone peripheral blood stem cell transplantation prednisone
Updated 6 times since 2017 Last updated: May 31, 2012 Started: Oct 31, 1999 Primary completion: Oct 31, 2002 Completion: Oct 31, 2002

Listed as NCT00004232, this PHASE1 trial focuses on Chronic Myeloproliferative Disorders and Graft Versus Host Disease and remains completed. Sponsored by National Cancer Institute (NCI), it has been updated 6 times since 1999, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Change History

6 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE1

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE1

  3. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE1

  4. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE1

  5. Feb 2017 — Jun 2018 [monthly]

    Completed PHASE1

▶ Show 1 earlier version

  1. Jan 2017 — Feb 2017 [monthly]

    Completed PHASE1

    First recorded

Oct 1999

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • National Cancer Institute (NCI)
  • Northwestern University
Data source: Northwestern University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

  • • Chicago, United States